Skip to main content

David Narrow, CEO

SONAVEX'S STORY

Rethinking ultrasound

For the world’s growing number of hemodialysis patients, 80% initiate dialysis on a catheter with the majority continuing to rely on a catheter six months later. That’s despite mortality rates being two to three times higher for patients with catheters as opposed to those with arteriovenous fistulae (AVF) created through surgeries. A Johns Hopkins spinoff, Sonavex has designed and developed a novel ultrasound solution that simplifies the collection of AVF data to support maturation assessment and minimize the time patients rely on catheters.

Sonavex also fills a longstanding gap in healthcare, meeting dialysis patients where they are — in dialysis clinics. The company’s patented EchoMark and EchoSure technologies are designed to enable any member of a patient’s care team to collect AVF volumetric flow rate, diameter and depth information at the dialysis clinic to support maturation assessment. With Sonavex, patients can see improved outcomes and providers can realize reduced costs.


- David Narrow, CEO

Sonavex in the Media

Brand Recognition

OUR APPROACH

We invest in early-stage startups all around the world, often helping overseas companies open their first American offices. Click below to tell us about your work.